Sat.Nov 20, 2021 - Fri.Nov 26, 2021

article thumbnail

New patent for Allergan Holdings drug VIBERZI

Drug Patent Watch

Annual Drug Patent Expirations for VIBERZI Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. It is available from one supplier. There are sixteen patents…. The post New patent for Allergan Holdings drug VIBERZI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 83
article thumbnail

Drug Channels News Roundup, November 2021: Specialty Pharmacy Checkup, Health Plan and Insulin, Gross-to-Net Bubble Update, and Amazon Redux

Drug Channels

Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

The Pharma Data

Combined efforts will work to build robust disease models while preserving privacy of large data sets from various research institutions and hospitals Collaboration to focus on four types of cancer. Sanofi blazoned moment an equity investment of$ 180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of$ 90 million for three times plus fresh exploration corner- grounded payments.

article thumbnail

Latest news on drug repurposing in oncology #12

The Anticancer Fund

26 November 2021 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Which pharmaceutical drugs have the most drug patents in Yugoslavia?

Drug Patent Watch

This chart shows the drugs with the most patents in Yugoslavia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Yugoslavia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Drug Channels News Roundup, November 2021: Health Plans and Insulin, Gross-to-Net Bubble Update, CVS & 340B, and Amazon Redux

Drug Channels

Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.

More Trending

article thumbnail

Drug Channels News Roundup, November 2021: Specialty Pharmacy, Health Plans and Insulin, Gross-to-Net Bubble Update, CVS & 340B, and Amazon Redux

Drug Channels

Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S.

article thumbnail

Drug Channels News Roundup, November 2021: Specialty Pharmacy Checkup, Insulin Profits, Gross-to-Net Bubble Update, CVS & 340B, Amazon Redux, and the FDA Appraises Soup

Drug Channels

Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: The State of Specialty Pharmacy 2021 How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon Plus, the FDA preps you for Thursday with a regulatory soup review.

article thumbnail

Which pharmaceutical companies have the most SPCs in Lithuania?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Lithuania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent for Sol-gel Technologies drug TWYNEO

Drug Patent Watch

Annual Drug Patent Expirations for TWYNEO Twyneo is a drug marketed by Sol-gel Technologies and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Sol-gel Technologies drug TWYNEO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

New patent expiration for Cumberland Pharms drug CALDOLOR

Drug Patent Watch

Annual Drug Patent Expirations for CALDOLOR Caldolor is a drug marketed by Cumberland Pharms and is included in one NDA. It is available from one supplier. There are ten patents…. The post New patent expiration for Cumberland Pharms drug CALDOLOR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors

The Pharma Data

A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute. The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by 50% or more in one-third of 45 patients with hard-to-treat high-grade gliomas, including glioblastomas, the most aggre

Drugs 52
article thumbnail

New patent expiration for Sanofi Aventis drug CHILDREN’S ALLEGRA ALLERGY

Drug Patent Watch

Annual Drug Patent Expirations for CHILDREN%27S+ALLEGRA+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com. The post New patent expiration for Sanofi Aventis drug CHILDREN’S ALLEGRA ALLERGY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Sanofi Aventis drug CHILDREN’S ALLEGRA HIVES

Drug Patent Watch

Annual Drug Patent Expirations for CHILDREN%27S+ALLEGRA+HIVES For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com. The post New patent expiration for Sanofi Aventis drug CHILDREN’S ALLEGRA HIVES appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Which pharmaceutical companies have the most tablet dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most tablet dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most tablet dosed drugs…. The post Which pharmaceutical companies have the most tablet dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Which pharmaceutical drugs have the most drug patents in Cyprus?

Drug Patent Watch

This chart shows the drugs with the most patents in Cyprus. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Cyprus? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent expiration for Viiv Hlthcare drug SELZENTRY

Drug Patent Watch

Annual Drug Patent Expirations for SELZENTRY Selzentry is a drug marketed by Viiv Hlthcare and is included in two NDAs. It is available from one supplier. There are three patents…. The post New patent expiration for Viiv Hlthcare drug SELZENTRY appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for Incyte Corp drug JAKAFI

Drug Patent Watch

Annual Drug Patent Expirations for JAKAFI Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent for Incyte Corp drug JAKAFI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

The Pharma Data

Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of care 1 Pivotal data on mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, showed high response rates in relapsed or refractory follicular lymphoma (FL) 2 HAVEN 6 phase III interim data demonstrated Hemlibra’s favourable safety and efficacy profile in people w

article thumbnail

Exposure to harmless coronaviruses boosts SARS-CoV-2 immunity

The Pharma Data

The population’s immunity to SARS-CoV-2, achieved either through infection or vaccination, is crucial to overcome the COVID-19 pandemic. A team of researchers led by the University of Zurich (UZH) has now discovered another component that contributes to SARS-CoV-2 immunity – previous antibody responses to other, harmless coronaviruses. “People who have had strong immune responses to other human coronaviruses also have some protection against SARS-CoV-2 infection,” says Al

article thumbnail

FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs

The Pharma Data

Approval is for Cytomegalovirus, a Type of Herpes Virus. Today, the U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35 kilograms) with post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV.

article thumbnail

Which pharmaceutical drugs have the most drug patents in European Patent Office?

Drug Patent Watch

This chart shows the drugs with the most patents in European Patent Office. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical drugs have the most drug patents in European Patent Office? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent expiration for Novartis drug PROMACTA

Drug Patent Watch

Annual Drug Patent Expirations for PROMACTA Promacta is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. There are twelve patents protecting…. The post New patent expiration for Novartis drug PROMACTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent expiration for Novartis drug PROMACTA KIT

Drug Patent Watch

Annual Drug Patent Expirations for PROMACTA+KIT Promacta Kit is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent expiration for Novartis drug PROMACTA KIT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Almost 100 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to Lower Income Countries Through COVAX

The Pharma Data

Company Welcomes Leadership Shown by the European Commission and EU Member States, plus Norway and Iceland to Help Advance Equitable Access to Our Vaccine. Johnson & Johnson (the Company) welcomes the decision of EU Member States along with Norway and Iceland (Team Europe) to donate almost 100 million doses of its COVID-19 vaccine through the COVAX Facility.

Vaccine 52
article thumbnail

AstraZeneca unveils The Discovery Centre (DISC) in Cambridge

The Pharma Data

State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem Sustainable environmental engineering aligned to Company’s zero carbon future. AstraZeneca will moment, in the presence of His Royal Highness The Prince of Wales, formally unveil The Discovery Centre ( Slice) in Cambridge, UK – a state-of-the- art exploration and development ( R&D) installation designed to the world’s loftiest environmental norms and accommodating over exploration scientis

article thumbnail

Which pharmaceutical companies have the most SPCs in Sweden?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

New patent for COVIS drug MAKENA

Drug Patent Watch

Annual Drug Patent Expirations for MAKENA Makena is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. There are eight patents protecting…. The post New patent for COVIS drug MAKENA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for COVIS drug MAKENA PRESERVATIVE FREE

Drug Patent Watch

Annual Drug Patent Expirations for MAKENA+PRESERVATIVE+FREE Makena Preservative Free is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. The generic ingredient…. The post New patent for COVIS drug MAKENA PRESERVATIVE FREE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

New patent for COVIS drug MAKENA (AUTOINJECTOR)

Drug Patent Watch

Annual Drug Patent Expirations for MAKENA+%28AUTOINJECTOR%29 Makena (autoinjector) is a drug marketed by Covis and is included in one NDA. It is available from two suppliers. There are eight patents…. The post New patent for COVIS drug MAKENA (AUTOINJECTOR) appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism

The Pharma Data

Today, the U.S. Food and Drug Administration approved Voxzogo (vosoritide) injection to improve growth in children five years of age and older with achondroplasia and open epiphyses (growth plates), meaning these children still have the potential to grow. Achondroplasia is the most common form of dwarfism. “Today’s approval fulfills an unmet medical need for more than 10,000 children in the United States and underscores the FDA’s commitment to help make new therapies available for rare diseases,

article thumbnail

Which pharmaceutical drugs have the most drug patents in Chile?

Drug Patent Watch

This chart shows the drugs with the most patents in Chile. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Chile? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Drug Channels News Roundup, November 2021: Health Plans and Insulin, Gross-to-Net Bubble Update, CVS & 340B, and Amazon Redux

Drug Channels

Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: How health plans profit—and patients lose—from insulin A fantastic new analysis of the gross-to-net bubble CVS acknowledges how its PBM profits from 340B Reconsidering Amazon P.S. Please join the nearly 13,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter.